Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Disruption of melatonin circadian rhythm production is related to multiple sclerosis severity: A preliminary study

Full text
Author(s):
Damasceno, Alfredo [1, 2] ; Moraes, Adriel Santos [2] ; Farias, Alessandro [2] ; Damasceno, Benito Pereira [1] ; Barbosa dos Santos, Leonilda Maria [2] ; Cendes, Fernando [1]
Total Authors: 6
Affiliation:
[1] Univ Estadual Campinas, UNICAMP, Dept Neurol, Campinas - Brazil
[2] Univ Estadual Campinas, UNICAMP, Neuroimmunol Unit, Dept Genet Evolut & Bioagents, Campinas - Brazil
Total Affiliations: 2
Document type: Journal article
Source: JOURNAL OF THE NEUROLOGICAL SCIENCES; v. 353, n. 1-2, p. 166-168, JUN 15 2015.
Web of Science Citations: 17
Abstract

Sunlight can influence the immune system independently of vitamin D, such as through melatonin production in the pineal gland. Inflammatory disorders can suppress nocturnal melatonin production, but only a few studies have investigated melatonin status in multiple sclerosis (MS). We aimed to study melatonin production in association with clinical and immunological data in MS patients. Eleven treated relapsing-remitting MS (RRMS) patients and eight controls underwent neurological examination and were assessed for fatigue severity and depressive symptoms. Inflammatory cytokines were analyzed in blood samples and concentration of 6-sulfatoxymelatonin (6-SMT) was determined in 24 h urine. Patients with an abnormal proportion of overnight 6-SMT (n = 8,72.7%) had higher disability and fatigue severity (p < 0.05). Overnight 6-SMT was inversely related with fatigue severity (p = 0.016), number of relapses in the previous 12 months (p = 0.010) and EDSS scores (p = 0.049). In conclusion, disruption of melatonin circadian rhythm production is frequent among RRMS patients and seemingly related to higher disability and fatigue scores. Future studies with larger sample size are necessary to establish melatonin status as a biomarker of disease severity in MS. (C) 2015 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 10/00885-4 - Longitudinal evaluation of cerebral atrophy and cortical thickness and its relationship with clinical and immunological factors in patients with multiple sclerosis
Grantee:Alfredo Damasceno
Support type: Scholarships in Brazil - Doctorate (Direct)